Associate Professor of Anaesthesia, Harvard Medical School
- Clinical Interests
- Anesthesia for general surgery and orthopedics
- Obstetric anesthesia
- Medical Education
- MD, University of Pennsylvania School of Medicine
- Residency, Massachusetts General Hospital
- Board Certifications
- Foreign Languages
- Boston: Massachusetts General Hospital
- Insurances Accepted
- Aetna Health Inc.
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- Cigna (PAL #'s)
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Medicare - ACD
- Neighborhood Health Plan - ACD
- Neighborhood Health Plan - PBO
- OSW - Maine
- OSW - New Hampshire
- OSW - Rhode Island
- Private Health Care Systems (PHCS)
- Railroad Medicare
- Senior Whole Health
- Tufts Health Plan
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
- Patient Age Group
- Research Summary
- I study the mechanisms of emergence and cognitive recovery from general anesthesia using a systems neuroscience approach. In current clinical practice, emergence from general anesthesia is treated as a passive process dictated by the pharmacokinetics of anesthetic drug clearance. My group discovered that methylphenidate (Ritalin) and dopamine agonists induce active emergence from general anesthesia, a process that we term "reanimation." We subsequently discovered that electrical stimulation of the ventral tegmental area (VTA), a key dopamine nucleus in the midbrain, also induces reanimation.
I currently direct a translational research program that studies the role of dopamine pathways in restoring consciousness and cognition after general anesthesia. In my laboratory, we combine intracranial stimulation, neurophysiological recordings, and cognitive testing in rodents to elucidate the neural circuits that govern reanimation, while my clinical research program tests novel methods to accelerate recovery of consciousness and cognition in surgical patients. Our long-term goal is to make general anesthesia safer by developing new therapeutic options for common clinical problems such as post-operative delirium and cognitive dysfunction.
The latest study from a Massachusetts General Hospital/Massachusetts Institute of Technology team investigating the mechanisms underlying general anesthesia finds that stimulating a specific group of neurons in mice produces signs of arousal even as the animals continue to receive the anesthetic drug isoflurane.
Stimulating one of two dopamine-producing regions in the brain was able to arouse animals receiving general anesthesia with either isoflurane or propofol.
The ability of the commonly used stimulant methylphenidate (Ritalin) to speed recovery from general anesthesia appears to apply both to the inhaled gas isoflurane, as previously reported, and to the intravenous drug propofol.
Administration of the commonly used stimulant drug methylphenidate was able to speed recovery from general anesthesia in an animal study conducted at MGH. The report is the first demonstration in mammals of what could be a safe and effective way to induce arousal from general anesthesia.
55 Fruit Street
Boston, MA 02114-2696